This has been addressed multiple times. Biotechs cannot market a drug that’s not FDA approved and they have to be careful how they get the leronlimab name out there before approval.

I don’t know if biotechs can market trial enrollment, either (for example, an announcement on their Facebook page and shared with other cancer pages). But it seems that with 50-60 patients waiting to be screened, CYDY shouldn’t have a problem getting patients for the mTNBC trial or basket trial (once approved).